GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Total Inventories

KNTPF (Kintor Pharmaceutical) Total Inventories : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Total Inventories?

Kintor Pharmaceutical's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Kintor Pharmaceutical's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was $42.11 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Kintor Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Kintor Pharmaceutical's Days Inventory for the six months ended in Dec. 2023 was 1,299.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Kintor Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.14.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Kintor Pharmaceutical Total Inventories Historical Data

The historical data trend for Kintor Pharmaceutical's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Total Inventories Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial - - 55.17 86.57 -

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.46 86.57 84.22 - 0.03

Kintor Pharmaceutical Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Kintor Pharmaceutical  (OTCPK:KNTPF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Kintor Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(63.794+0.75 * 0+0.5 * 0-57.578
-0-0)/429.849
=0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kintor Pharmaceutical's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=42.108/5.914*365 / 2
=1,299.41

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kintor Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=5.914 / 42.108
=0.14

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kintor Pharmaceutical's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=42.108 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Kintor Pharmaceutical Total Inventories Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

Kintor Pharmaceutical Headlines